5HPP-33

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H21NO3
Molecular Weight	323.3856
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=CC=CC(C(C)C)=C1N2C(=O)C3=C(C=C(O)C=C3)C2=O

InChI

InChIKey=LAKWINYVWJPHQW-UHFFFAOYSA-N

InChI=1S/C20H21NO3/c1-11(2)14-6-5-7-15(12(3)4)18(14)21-19(23)16-9-8-13(22)10-17(16)20(21)24/h5-12,22H,1-4H3

HIDE SMILES / InChI

Molecular Formula	C20H21NO3
Molecular Weight	323.3856
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tubulin polymerization 1 Target ID: Tubulin polymerization Sources: https://www.ncbi.nlm.nih.gov/pubmed/15603947	Inhibitor 8504
NF-kappaB activation 1 Target ID: NF-kappaB activation Sources: https://www.ncbi.nlm.nih.gov/pubmed/17845850 \| https://www.ncbi.nlm.nih.gov/pubmed/23018603	Inhibitor 8504

PubMed

Title	Date	PubMed
Embryonic vascular disruption adverse outcomes: Linking high-throughput signaling signatures with functional consequences.	2017-08	28414088
Embryonic vascular disruption adverse outcomes: Linking high throughput signaling signatures with functional consequences.	2017-06	28527947
Thalidomide (5HPP-33) suppresses microtubule dynamics and depolymerizes the microtubule network by binding at the vinblastine binding site on tubulin.	2015-03-31	25747795
Structure-activity relationship studies of thalidomide analogs with a taxol-like mode of action.	2013-12-15	24169233
A computational model predicting disruption of blood vessel development.	2013-04	23592958
Novel compound SK-1009 suppresses interleukin-6 expression through modulation of activation of nuclear factor-kappaB pathway.	2012	23018603
Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide.	2008-02	18204782
New tubulin polymerization inhibitor derived from thalidomide: implications for anti-myeloma therapy.	2008	18393844
Inhibitors of NF-kappaB derived from thalidomide.	2007-11-01	17845850
Development of tubulin-polymerization inhibitors based on the thalidomide skeleton.	2007-06	17541201
A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities.	2006-02	16505120
Angiogenesis inhibitors derived from thalidomide.	2005-12-15	16183272
Cell differentiation inducers derived from thalidomide.	2005-07-01	15936192
Tubulin-polymerization inhibitors derived from thalidomide.	2005-01-17	15603947

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:43:53 GMT 2025` Edited by `admin` on `Mon Mar 31 22:43:53 GMT 2025`
Record UNII	5SZ69PBV5B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-BIS(1-METHYLETHYL)PHENYL)-5-HYDROXY-

Preferred Name

English

5HPP-33

Code

English

2-(2,6-DIISOPROPYLPHENYL)-5-HYDROXYISOINDOLINE-1,3-DIONE

Systematic Name

English

2-(2,6-BIS(1-METHYLETHYL)PHENYL)-5-HYDROXY-1H-ISOINDOLE-1,3(2H)-DIONE

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID1046970

Created by admin on Mon Mar 31 22:43:53 GMT 2025 , Edited by admin on Mon Mar 31 22:43:53 GMT 2025

PRIMARY

PUBCHEM

11723708

Created by admin on Mon Mar 31 22:43:53 GMT 2025 , Edited by admin on Mon Mar 31 22:43:53 GMT 2025

PRIMARY

CAS

105624-86-0

Created by admin on Mon Mar 31 22:43:53 GMT 2025 , Edited by admin on Mon Mar 31 22:43:53 GMT 2025

PRIMARY

FDA UNII

5SZ69PBV5B

Created by admin on Mon Mar 31 22:43:53 GMT 2025 , Edited by admin on Mon Mar 31 22:43:53 GMT 2025

PRIMARY